F16.11

Clinical Causes: Experimentation with recreational drugs during adolescence or adulthood. Use of hallucinogenic substances as a way to cope with psychological or emotional issues. Influence of social environments that promote drug use. Availability and easy access to hallucinogenic drugs like LSD, psilocybin mushrooms, or PCP. Genetic or biological predispositions that contribute to substance use disorders.

Key Symptoms: Past episodes of seeing or hearing things that aren't there (visual or auditory hallucinations). Altered perceptions of reality, space, or time during substance use. Episodes of confusion or disorientation when under the influence. Mood swings or changes in behavior related to previous drug use. Cravings or a strong desire to use hallucinogens again, particularly during early remission.

Diagnosis Path: Diagnosing hallucinogen use disorder involves a comprehensive clinical assessment, including patient history and symptom review. For a diagnosis of 'in remission,' the healthcare provider will determine that the individual has not used hallucinogens for a significant period, usually at least three months, and that the symptoms of use disorder have diminished or disappeared. The assessment also considers whether the person is in early remission (less than 12 months abstinent) or sustained remission (more than 12 months abstinent).

Treatment Protocols: Psychological counseling or therapy, such as cognitive-behavioral therapy (CBT), to address underlying issues and develop coping skills. Support groups or peer support programs focused on substance use recovery. Medical follow-up to monitor mental health and address any emergent symptoms. Relapse prevention strategies to help individuals recognize and respond to triggers. Lifestyle changes promoting holistic well-being, including stress management, healthy routines, and social support.